Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2024

Buhagiar AF, Kleaveland B. To kill a microRNA: emerging concepts in target-directed microRNA degradation. Nucleic Acids Res. 2024;52(4):1558-1574.

Nicholson JG, Cirigliano S, Singhania R, Haywood C, M Dadras S, Yoshimura M, et al. Chronic hypoxia remodels the tumor microenvironment to support glioma stem cell growth. Acta Neuropathol Commun. 2024;12(1):46.

Yang HS. Machine Learning for Sepsis Prediction: Prospects and Challenges. Clin Chem. 2024;70(3):465-467.

Ntiri M, Nazarian A, Magro C, Alexis AF. Nodular (keloidal) scleroderma: A case series of 5 patients. JAAD Case Rep. 2024;49:135-139.

Centeno BA, Saieg M, Siddiqui MT, Perez-Machado M, Layfield LJ, Weynand B, et al. The World Health Organization Reporting System for Pancreaticobiliary Cytopathology: Overview and Summary. Cancer Cytopathol. 2024;132(7):396-418.

Gordon ER, Kwinta BD, Schreidah CM, Fahmy LM, Adeuyan O, Queen D, et al. Cutaneous lymphoproliferative disorders after COVID-19 vaccination: clinical presentation, histopathology, and outcomes. Leuk Lymphoma. 2024;65(1):48-54.

Furtado LV, Bifulco C, Dolderer D, Hsiao SJ, Kipp BR, Lindeman NI, et al. Recommendations for Tumor Mutational Burden Assay Validation and Reporting: A Joint Consensus Recommendation of the Association for Molecular Pathology, College of American Pathologists, and Society for Immunotherapy of Cancer. J Mol Diagn. 2024;26(8):653-668.

Magro CM, Kalomeris T, Shreve CR, Geyer JT, Patel SS. Subcutaneous panniculitic-like T-cell lymphoma localized to a site of peginterferon alfa-2a administration. Leuk Lymphoma. 2024:1-9.

Quaranta P, Basso-Ricci L, Hernández RJ, Pacini G, Naldini MM, Barcella M, et al. Circulating Hematopoietic Stem/Progenitor Cells subsets contribute to human hematopoietic homeostasis. Blood. 2024.

Conway J, Magro CM, Lipner SR. Expanding the Differential Diagnosis of the Painful Nail: A Case of an Onychopapilloma with Neuroma. Case Rep Dermatol. 2024;16(1):88-93.